071sek
0,7 %
Date:2025-05-14Time:16:55:31Latest report:Q4-2024List:SpotlightTicker:CHOSA
Market Cap:50 msekEnterprise Value:44 msekNet Sales:- msekEarnings:-9,59 msekEmployees:0ISIN:SE0007784319

Ratios

10-year key figure history for CHOSA Oncology turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for CHOSA Oncology with index and moving average MA50 and MA200.

Stockprice:0,71
MA50:0,73
MA200:0,83
Price/MA200:-14,9 %
RSI (14):52,6
Price/MA50:-3,7 %

Description

Chosa Oncology, Danish -Swedish biotechnology company, has developed the iCIP platform, which includes a liposomal formulation of cisplatin (LiPlaCis) and the companion diagnostic (DRP) tool detecting patients who benefits the most of the cisplatin treatment. The recently achieved clinical phase 2b results mean that the Company is now gearing up the business development activities to find partners for partnership or trade deal.

Biotechnology